Mesoblast’s Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science
Results Show Sustained Improvement In Pain And Function Over 24 Months Following A Single Intra-Disc Cell Injection
MELBOURNE, Australia and NEW YORK, Aug. 01, 2016 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the 24-month results from the 100-patient, four-arm, randomized, placebo-controlled Phase 2 trial of its chronic low back pain (CLBP) product candidate MPC-06-ID were presented at the 24th Annual Scientific Meeting of the Spine Intervention Society (SIS) held in New Orleans July 27-30, and received the 2016 Best Basic Science Abstract award at the meeting. [Read more…]